Farallon Capital Management, L.L.C. / CRNX
Farallon Capital Management, L.L.C.’s Crinetics Pharmaceuticals In Position
Does Farallon Capital Management, L.L.C. own Crinetics Pharmaceuticals In (CRNX)? Yes — 8.34M shares worth $303M (+1.64% of its 13F portfolio) as of Q1 2026, up from 6.93M shares the prior filed quarter.
Position Value
$303M
Q1 2026
Shares
8.34M
% of Portfolio
+1.64%
Quarters Held
12
currently held
Position History CRNX
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 8.34M | $303M | +1.64% |
| Q4 2025 | 6.93M | $323M | +1.52% |
| Q3 2025 | 5.77M | $240M | +0.98% |
| Q2 2025 | 4.65M | $134M | +0.56% |
| Q1 2025 | 4.61M | $154M | +0.83% |
| Q4 2024 | 4.08M | $208M | +1.06% |
| Q3 2024 | 1.16M | $59M | +0.29% |
| Q2 2024 | 497.0K | $22M | +0.10% |
| Q1 2024 | 5.0K | $234,050 | 0.00% |
| Q4 2023 | 122.9K | $4M | +0.02% |
| Q3 2023 | 361.9K | $11M | +0.05% |
| Q4 2018 | 95.4K | $3M | +0.02% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Farallon Capital Management, L.L.C.’s full portfolio or all institutional holders of CRNX.